Kesmalea Therapeutics

Kesmalea Therapeutics is a pioneering force in biotechnology research, dedicated to creating innovative medicines through the transformation of protein degradation. Kesmalea Therapeutics is at the forefront of developing a pipeline of novel therapeutics, leveraging its unique SELFTAC® platform to convert large protein degraders into small molecules. This groundbreaking approach combines the potency of protein degradation with key benefits such as oral bioavailability and central nervous system (CNS) penetration.

Kesmalea Therapeutics' research initiatives are currently focused on oncology and CNS diseases, with a broad vision for future applications. The company's foundation is built upon the scientific contributions of its founder, Harry Finch, Ph.D., a distinguished medicinal chemist and entrepreneur. With its headquarters in London, Kesmalea Therapeutics is committed to advancing the field of protein degradation and delivering transformative therapies to patients in need. Kesmalea Therapeutics is dedicated to improve and revolutionize the therapeutics industry.

Located in London, GB, Kesmalea Therapeutics is poised for significant growth and is actively seeking collaborations to expand its impact. We invite the management of Kesmalea Therapeutics to create a customized and exclusive company showcase and product listing on our platform, highlighting the groundbreaking work being done in biotechnology research.